For instance, the association between pharmacological inhibitors such as ralimetinib (a MAPK14 inhibitor) and SLiM-based small molecules interfering with MAPK signaling activation may prove an effective therapeutic approach to hamper MAPK-dependent CRC development and progression [117]. This evidence concerns the gene MAPK14 and colorectal carcinoma.